A New Molecularly Targeted Therapeutic for Acute Myeloid Leukemia

The new therapeutic was approved by the FDA for treating patients whose leukemia tests positive for a mutation in the IDH1 gene.

The U.S. Food and Drug Administration (FDA) recently approved a new molecularly targeted therapeutic for treating certain patients with acute myeloid leukemia (AML). They also approved a companion diagnostic test to identify those patients eligible to receive it – adults whose AML is progressing despite treatment and that harbors certain mutations in the IDH1 gene.

AML is the most common cause of death from leukemia in the United States, according to National Cancer Institute statistics. In 2018, 10,670 people are expected to die from the disease.

In 2017, we saw substantive gains in precision medicine for patients with AML when the FDA approved two molecularly targeted therapeutics for treating this devastating disease, midostaurin (Rydapt) and enasidenib (Idhifa).

The development of midostaurin and enasidenib stemmed from research into the biology of AML, in particular the genetic mutations that promote its development. Midostaurin and enasidenib target the proteins produced by two of the most commonly mutated genes in AML, FLT3 and IDH2, respectively.

IDH1 is another gene mutated in a significant proportion of AML cases, making the altered proteins produced by mutations in this gene a prime therapeutic target. These are the proteins targeted by ivosidenib.

The approval of ivosidenib was based on results from a phase 1 clinical trial, some of which were published in The New England Journal of Medicine. The results showed that more than 30 percent of patients treated with ivosidenib had complete remission, meaning that there was no evidence of leukemia, with either full or partial recovery of blood counts. These responses lasted for a median of 8.2 months.

This article was adapted with permission from a post on the AACR's official blog, CANCER RESEARCH Catalyst. The FDA approval was rendered on July 20, 2018. Find out more about the decision on the FDA website.

Last year the AACR provided over $64 million in grants and awards funding lifesaving cancer research. There are many ways you can support our mission to prevent and cure all cancers. Take Action

The American Association for Cancer Research (AACR) is a 501c3 registered nonprofit organization with offices at 615 Chestnut Street, 17th Floor, Philadelphia, PA 19106 | 215.440.9300